Fisher Asset Management LLC Sells 3,415 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Fisher Asset Management LLC lowered its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 158,369 shares of the medical equipment provider’s stock after selling 3,415 shares during the quarter. Fisher Asset Management LLC’s holdings in Lantheus were worth $9,819,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Tucker Asset Management LLC raised its stake in shares of Lantheus by 239.0% in the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 282 shares during the period. First Horizon Advisors Inc. raised its stake in shares of Lantheus by 97.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 225 shares during the period. Covestor Ltd raised its stake in shares of Lantheus by 62.7% in the 3rd quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 203 shares during the period. Parkside Financial Bank & Trust raised its stake in shares of Lantheus by 36.6% in the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 156 shares during the period. Finally, NBC Securities Inc. acquired a new stake in shares of Lantheus in the 3rd quarter valued at about $46,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Trading Down 0.0 %

Lantheus stock opened at $75.51 on Tuesday. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $100.85. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.55 and a current ratio of 4.84. The stock has a market capitalization of $5.23 billion, a P/E ratio of 11.53 and a beta of 0.52. The stock has a 50-day simple moving average of $62.82 and a 200 day simple moving average of $62.75.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. The business had revenue of $354.00 million during the quarter, compared to analysts’ expectations of $350.44 million. Analysts expect that Lantheus Holdings, Inc. will post 5.96 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the sale, the director now owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 94,545 shares of company stock worth $6,169,936. Company insiders own 2.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Friday. JMP Securities restated a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a report on Friday, February 23rd. Mizuho raised their price objective on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday. Truist Financial raised their price objective on Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a report on Friday. Finally, B. Riley raised their price objective on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a report on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $99.17.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.